Lucid Diagnostics Inc. (LUCD) stock forecast & analysis
0.4110
NasdaqCM · USDDelayed by 15 minutes
Up: +0.0833, +25.4%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.4321
- Previous close
- 0.3277
- Day range
- 0.3880 – 0.4500
- 52-week range
- 0.3030 – 1.63
- Volume (shares)
- 111.80M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 190.95M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.12
- Market cap
- 78.48M
Market Scanner’s AI analysis of Lucid Diagnostics Inc. (LUCD), updated October 2026: Lucid Diagnostics' reimbursement progress and revenue growth contrasted with technical downtrend
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Lucid Diagnostics Inc. (LUCD) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Lucid Diagnostics' reimbursement progress and revenue growth contrasted with technical downtrend
Recent analyses for Lucid Diagnostics (LUCD) covered significant progress in securing Medicare reimbursement for its EsoGuard® product and closing a $15 million financing round. The company also reported year-over-year quarterly revenue growth of 26.7% and an improvement in gross profit, though the overall fiscal year 2025 showed a gross loss. Technical indicators presented a bearish outlook, with the price trading significantly below its 50-day and 200-day SMAs, despite a potentially oversold RSI.
LUCD news & sentiment
News coverage highlighted positive developments regarding Medicare reimbursement and financing, alongside quarterly revenue growth. Social media discussions focused on the company's ongoing progress in these areas.
LUCD technical picture
Technical indicators presented a bearish outlook for LUCD, with the last close significantly below both the 50-day and 200-day SMAs, indicating a strong downtrend. Momentum readings from the MACD confirmed bearish momentum, while the RSI was just above the oversold threshold, suggesting potential for a short-term bounce but overall weakness.
Fundamentals
Lucid Diagnostics reported strong year-over-year quarterly revenue growth and an improvement in gross profit, moving from negative to positive. The company's fiscal year 2025 ended with a gross loss and a net loss, though its cash position and debt levels were noted, alongside current and quick ratios.
Factors discussed — upside
- Year-over-year quarterly revenue growth of 26.7%
- Improvement in gross profit from negative to positive in the latest quarter
- Secured Medicare reimbursement for EsoGuard®
- Closed a $15 million financing round
- Secured commercial coverage policies for EsoGuard® from multiple health plans
Factors discussed — risks
- Price significantly below 50-day and 200-day SMAs
- 10-day EMA above current price, indicating short-term bearish momentum
- MACD below zero, confirming bearish momentum
- Fiscal year 2025 gross profit was negative
- Net income for fiscal year 2025 was negative
- Reimbursement progress
- Revenue growth
- Technical indicators
- Financing efforts
Summary updated .
LUCD technical indicators
Common technical indicators for LUCD, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.77 | Price below |
| 10-day exponential moving average | 0.44 | Price below |
| Relative strength index (14-day) | 30.25 | Neutral |
| MACD line (12/26/9) | -0.1194 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.28 – 0.85 | Price inside the bands |
Analyses
Recent LUCD.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-26 LUCD.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Lucid Diagnostics Inc.?
- The bull case for Lucid Diagnostics centers on significant progress in reimbursement for its EsoGuard® product, including Medicare coverage and commercial health plan policies, alongside a successful $15 million financing round. The company has also demonstrated year-over-year quarterly revenue growth of 26.7% and improved gross profit margins.
- What are the risks for Lucid Diagnostics Inc.?
- Risks for Lucid Diagnostics include a technical downtrend indicated by its price being significantly below key moving averages and a short-term bearish momentum. The company's fiscal year 2025 financial performance showed a gross loss and a net loss, despite recent improvements in quarterly gross profit.
- Is Lucid Diagnostics Inc. bullish or bearish?
- Recent AI analyses of Lucid Diagnostics Inc. examined factors on both sides. Discussed upside: The bull case for Lucid Diagnostics centers on significant progress in reimbursement for its EsoGuard® product, including Medicare coverage and commercial health plan policies, alongside a successful $15 million financing round. The company has also demonstrated year-over-year quarterly revenue growth of 26.7% and improved gross profit margins. Discussed risks: Risks for Lucid Diagnostics include a technical downtrend indicated by its price being significantly below key moving averages and a short-term bearish momentum. The company's fiscal year 2025 financial performance showed a gross loss and a net loss, despite recent improvements in quarterly gross profit. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Lucid Diagnostics Inc.?
- News coverage highlighted positive developments regarding Medicare reimbursement and financing, alongside quarterly revenue growth. Social media discussions focused on the company's ongoing progress in these areas.
- How does Market Scanner analyse Lucid Diagnostics Inc.?
- Every analysis of Lucid Diagnostics Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Lucid Diagnostics Inc.?
The bull case for Lucid Diagnostics centers on significant progress in reimbursement for its EsoGuard® product, including Medicare coverage and commercial health plan policies, alongside a successful $15 million financing round. The company has also demonstrated year-over-year quarterly revenue growth of 26.7% and improved gross profit margins.
What are the risks for Lucid Diagnostics Inc.?
Risks for Lucid Diagnostics include a technical downtrend indicated by its price being significantly below key moving averages and a short-term bearish momentum. The company's fiscal year 2025 financial performance showed a gross loss and a net loss, despite recent improvements in quarterly gross profit.
Is Lucid Diagnostics Inc. bullish or bearish?
Recent AI analyses of Lucid Diagnostics Inc. examined factors on both sides. Discussed upside: The bull case for Lucid Diagnostics centers on significant progress in reimbursement for its EsoGuard® product, including Medicare coverage and commercial health plan policies, alongside a successful $15 million financing round. The company has also demonstrated year-over-year quarterly revenue growth of 26.7% and improved gross profit margins. Discussed risks: Risks for Lucid Diagnostics include a technical downtrend indicated by its price being significantly below key moving averages and a short-term bearish momentum. The company's fiscal year 2025 financial performance showed a gross loss and a net loss, despite recent improvements in quarterly gross profit. These are descriptive observations, not a recommendation.
What is the latest sentiment on Lucid Diagnostics Inc.?
News coverage highlighted positive developments regarding Medicare reimbursement and financing, alongside quarterly revenue growth. Social media discussions focused on the company's ongoing progress in these areas.
How does Market Scanner analyse Lucid Diagnostics Inc.?
Every analysis of Lucid Diagnostics Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh LUCD.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.